BIIB - Biogen Inc.
| Previous Close | 227.67 |
| Open | 228.76 |
| Bid | 232.01 x 800 |
| Ask | 233.62 x 800 |
| Day's Range | 227.66 - 232.95 |
| 52 Week Range | 216.12 - 388.67 |
| Volume | 1,447,649 |
| Avg. Volume | 2,585,637 |
| Market Cap | 44.941B |
| Beta (3Y Monthly) | 1.62 |
| PE Ratio (TTM) | 10.02 |
| EPS (TTM) | 23.14 |
| Earnings Date | Jul 22, 2019 - Jul 26, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 258.79 |
- Motley Fool•1 hour ago
3 Big Drugmakers Most Likely to Make Acquisitions After Pfizer's Surprise Deal
Pfizer could be only the first of several to spend billions buying smaller biotech.
- Zacks•23 hours ago
AstraZeneca Gives Detailed Data From Calquence Leukemia Study
AstraZeneca's (AZN) Calquence monotherapy prolongs progression-free survival significantly in relapsed or refractory CLL patients compared to Roche's Rituxan.
- Zacks•5 days ago
Biogen (BIIB) Gains But Lags Market: What You Should Know
Biogen (BIIB) closed the most recent trading day at $230.86, moving +0.19% from the previous trading session.
CNW Group•5 days agoOntario grants broader access to SPINRAZA™ (nusinersen) for patients living with spinal muscular atrophy (SMA)
MISSISSAUGA, ON, June 13, 2019 /CNW/ - Biogen Canada is pleased to announce that patients in Ontario living with spinal muscular atrophy (SMA) now have broader publicly funded access to SPINRAZA™ (nusinersen), the first and only treatment approved in Canada for SMA.
- Simply Wall St.•6 days ago
Biogen Inc. (NASDAQ:BIIB) Insiders Increased Their Holdings
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
- Zacks•6 days ago
Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash
Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
- GlobeNewswire•7 days ago
Biogen to Present New Safety and Efficacy Data on Biosimilars and Estimates 1.8 Billion Euros in Savings for the European Healthcare System in 2019
Data to be presented at the European Congress of Rheumatology (EULAR) 2019 highlight real-world evidence confirming the safety and efficacy of anti-TNF biosimilars and high.
- Zacks•11 days ago
Biogen (BIIB) Outpaces Stock Market Gains: What You Should Know
Biogen (BIIB) closed the most recent trading day at $227.33, moving +1.33% from the previous trading session.
- Zacks•11 days ago
Celgene's Filing for Ozanimod Accepted for Review in US/EU
The FDA and the EMA accept Celgene's (CELG) multiple sclerosis candidate, ozanimod, for review.
- GlobeNewswire•11 days ago
Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Million
Nasdaq: NITE), a clinical-stage gene therapy company, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. As a result of the acquisition, Biogen now has added two mid- to late-stage clinical assets, as well as preclinical programs, in ophthalmology.
- Barrons.com•12 days ago
Biogen Stock Is Slipping Because Investors Don’t Buy Its News on Lou Gehrig’s Disease
In a webcast, the company outlined a strategy that focuses in the near term on rarer forms of amyotrophic lateral sclerosis, commonly known as Lou Gehrig’s disease.
- Zacks•18 days ago
Biogen Reports Interim Phase III Data on Diroximel Fumarate
Biogen (BIIB) announces new interim results from phase III EVOLVE-MS-1 study, which showed that the diroximel fumarate was generally well tolerated in people with relapsing MS.
Market Realist•18 days agoWhat Are Gilead Sciences’ Key Growth Drivers in 2019?
Gilead Sciences or Biogen: Which Is the Better Biotech Pick?(Continued from Prior Part)Growth driversSince the second quarter of 2016, Gilead Sciences (GILD) has been reporting major YoY (year-over-year) revenue declines, mainly due to its lower HCV
- Zacks•18 days ago
Roche (RHHBY) Up 6.3% YTD on Strong Demand for New Drugs
Roche's (RHHBY) performance has been strong in the year so far, driven by solid growth of Ocrevus, Perjeta, Tecentriq and Hemlibra.
Market Realist•18 days agoHow Is Biogen’s Tecfidera Positioned in 2019?
Gilead Sciences or Biogen: Which Is the Better Biotech Pick?(Continued from Prior Part)MS revenue performance in the first quarterIn the first quarter, Biogen (BIIB) reported MS (multiple sclerosis) franchise revenue of ~$2.1 billion including
Market Realist•18 days agoHow Is Gilead Sciences Revamping Its NASH Strategy in 2019?
Gilead Sciences or Biogen: Which Is the Better Biotech Pick?(Continued from Prior Part)NASH failed trialsOn February 11, Gilead Sciences (GILD) issued a press release announcing the top line results from its Phase 3 STELLAR-4 study evaluating the
Market Realist•19 days agoHow Is Biogen’s Alzheimers’ Disease Pipeline Positioned in 2019?
Gilead Sciences or Biogen: Which Is the Better Biotech Pick?(Continued from Prior Part)Failed programOn March 21, Biogen (BIIB) issued a press release announcing the discontinuation of its Phase 3 trials ENGAGE and EMERGE evaluating its leading
- Zacks•19 days ago
PDL BioPharma's Royalties Help, Heavy Partner Reliance Hurts
PDL BioPharma (PDLI) aims to acquire and manage high-yielding assets and maximize shareholder value. Blindly falling back on partners for royalties is a persistent concern.
- GlobeNewswire•19 days ago
New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis
Biogen Inc. (BIIB) announced today new interim data from the ongoing open-label, pivotal EVOLVE-MS-1 study indicate that the investigational treatment diroximel fumarate was generally well tolerated in people with relapsing multiple sclerosis (MS). Diroximel fumarate, a novel oral fumarate candidate in development with Alkermes plc (ALKS), is under review with the U.S. Food and Drug Administration with a PDUFA (Prescription Drug User Fee Act) target action date in the fourth quarter of 2019.
- Barrons.com•19 days ago
The Case for a Biogen Acquisition — and 3 Potential Targets
Biogen stock has been through the wringer in 2019, and some think an acquisition could get it back on track. Here are several potential takeover targets.
- Zacks•20 days ago
Biogen (BIIB) Dips More Than Broader Markets: What You Should Know
In the latest trading session, Biogen (BIIB) closed at $223.40, marking a -0.95% move from the previous day.
- Zacks•20 days ago
Celgene's Revlimid-Rituximab Combo Gets FDA Nod for Lymphoma
Celgene's (CELG) Revlimid in combination with a rituximab product gets FDA approval for the treatment of adult patients with previously treated follicular lymphoma or marginal zone lymphoma.
- Zacks•22 days ago
Roche Gets FDA Nod for Expansion of Cobas 6800/8800 Systems
Roche (RHHBY) gets FDA clearance for the expansion of its leading testing menu.
- Reuters•25 days ago
UPDATE 5-Novartis $2 mln gene therapy for rare disorder is world's most expensive drug
ZURICH/NEW YORK, May 24, (Reuters) - Swiss drugmaker Novartis on Friday won U.S. approval for its gene therapy Zolgensma for spinal muscular atrophy (SMA), the leading genetic cause of death in infants, and priced the one-time treatment at a record $2.125 million. The Food and Drug Administration approved Zolgensma for children under the age of two with SMA, including those not yet showing symptoms. "This is potentially a new standard of care for babies with the most serious form of SMA," said Dr. Emmanuelle Tiongson, a pediatric neurologist at Children's Hospital Los Angeles who has provided Zolgensma to patients under an expanded access program.
- Zacks•25 days ago
Biogen (BIIB) Down 0.3% Since Last Earnings Report: Can It Rebound?
Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
